

Arif Ali Awan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6488151/publications.pdf>

Version: 2024-02-01

23
papers

171
citations

1478505

6
h-index

1199594

12
g-index

23
all docs

23
docs citations

23
times ranked

112
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Supportive Care in Cancer, 2021, 29, 925-943.	2.2	28
2	De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Research and Treatment, 2019, 176, 507-517.	2.5	23
3	A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer. Supportive Care in Cancer, 2020, 28, 4891-4899.	2.2	17
4	Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT). Breast Cancer Research and Treatment, 2019, 177, 93-101.	2.5	15
5	Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey. Journal of Bone Oncology, 2021, 26, 100339.	2.4	10
6	The Impact of Foundation Medicine Testing on Cancer Patients: A Single Academic Centre Experience. Frontiers in Oncology, 2021, 11, 687730.	2.8	9
7	A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. Breast Cancer Research and Treatment, 2019, 178, 337-345.	2.5	7
8	Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer. Journal of Bone Oncology, 2021, 26, 100343.	2.4	6
9	A prospective multi-centre, randomized study comparing the addition of tapering dexamethasone to other standard of care therapies for taxane-associated pain syndrome (TAPS) in breast cancer patients. Supportive Care in Cancer, 2021, 29, 5787-5795.	2.2	6
10	Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey. Breast Cancer Research and Treatment, 2021, 187, 477-486.	2.5	6
11	Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. Supportive Care in Cancer, 2021, 29, 6903-6912.	2.2	6
12	De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?. Journal of Oncology Practice, 2018, 14, 465-467.	2.5	5
13	Optimal frequency of scans for patients on cancer therapies: A population kinetics assessment. Cancer Medicine, 2019, 8, 6871-6886.	2.8	5
14	Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. Supportive Care in Cancer, 2022, 30, 3977-3984.	2.2	5
15	A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer. Current Oncology, 2021, 28, 5073-5083.	2.2	5
16	A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management. Breast Cancer Research and Treatment, 2021, 185, 533-547.	2.5	4
17	Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation. Journal of Bone Oncology, 2021, 27, 100351.	2.4	4
18	A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Breast, 2021, 58, 42-49.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors. JAMA Network Open, 2022, 5, e2219128.	5.9	4
20	Efficacy and toxicity of extending bone modifying agents beyond two years for bone metastases in breast or castrate-resistant prostate cancer patients: A systematic review.. Journal of Clinical Oncology, 2020, 38, e24083-e24083.	1.6	1
21	Abstract OT1-01-01: A randomized, pragmatic trial investigating the timing of radiotherapy and endocrine in patients with early stage breast cancer (REaCT-RETT trial). Cancer Research, 2022, 82, OT1-01-01-OT1-01-01.	0.9	1
22	Abstract PS9-47: A scoping review characterizing "choosing wisely" recommendations for breast cancer management. , 2021, , .		0
23	Intratumoral (IT) INT230-6 can cause tumor necrosis in vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).. Journal of Clinical Oncology, 2022, 40, 605-605.	1.6	0